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A Ab bs st tr ra ac ct t    In the absence of preventative therapy, reinfection of allografts with hepatitis 
B virus (HBV) after orthotopic liver transplantation (OLT) resulted in dismal 
allograft and patient survival. Major advances in the management of HBV-
infected recipients of OLT during the past 15 years have steadily reduced the 
rate of reinfection, resulting in improved outcomes. Initially, long-term use of 
hepatitis B immune globulin (HBIG) as a source of anti-HBs antibodies was 
effective in preventing or delaying reinfection. Lamivudine monotherapy 
made it possible to suppress HBV replication prior to OLT, markedly 
decreasing the risk of reinfection. Although lamivudine monotherapy used 
before and after OLT could prevent reinfection, its effectiveness was limited 
by progressive development of lamivudine-resistant mutant infections. 
Combination therapy with HBIG and lamivudine after OLT reduced both 
HBV recurrence and the risk of lamivudine resistance even in patients with 
active HBV replication. Introduction of adefovir provided a safe, alternative 
oral antiviral able to treat effectively lamivudine-resistant mutants HBV. 
Available strategies to prevent reinfection have resulted in OLT outcomes for 
HBV-infected patients comparable to those for patients transplanted for non-
HBV indications. In the future, combination therapies of HBIG and both 
nucleoside and/or nucleotide agents will undoubtedly be optimized. 
Development of new drugs to treat HBV will increase opportunities to 
combine agents to enhance safety, efficacy and prevent emergence of HBV 
escape mutants. New vaccines and adjuvants may make it possible to 
generate anti-HBs in immunosuppressed patients, eliminating the need for 
HBIG.  
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1.  Introduction 
Innovations in the management of HBV infection before and after orthotopic liver transplantation (OLT) have revolutionized 
outcomes for hepatitis B virus (HBV)-infected recipients. In the absence of preventative therapies, OLT for patients with acute or 
chronic replicating HBV infections resulted in universal reinfection of the allograft, progressive graft failure and excessive mortality, 
even with retransplantation [1-3]. Thus, HBV-related liver disease was initially regarded as a contraindication to OLT [4] and was 
excluded as an indication by Medicare in the U.S.A. [5]. Over the past 15 years, sequential application of therapeutic strategies to 
prevent recurrent HBV infection after OLT and to inhibit HBV replication before and after OLT has steadily improved outcomes [6-
8]. Indefinite administration of passive immunoprophylaxis with hepatitis B immune globulin (HBIG, a source of high titer, 
polyvalent anti-HBs antibodies) resulted in a significant reduction in recurrent hepatitis B, especially among recipients without 
active HBV replication at the time of OLT [9-12]. Pre-OLT inhibition of HBV replication using lamivudine (LAM) rendered 
patients with active replication eligible for transplantation, prevented recurrence post-OLT (unless LAM-resistant escape mutations 
developed) and improved the outcome of patients who became reinfected [13-17]. The combination of HBIG and lamivudine 
enhanced prevention of HBV reinfection [14,18], and the advent of adefovir dipoxil (ADV) provided an safe and efficacious 
therapeutic option for patients with LAM-resistant infection [19]. As a result of this progress in prevention and treatment of HBV 
reinfection, acute or chronic hepatitis B is now universally accepted as an excellent indication for OLT [8].  
Transplantation of livers from donors with isolated anti-HBc-positivity (i.e. negative for HBsAg and anti-HBs) has resulted in 
additional challenges, since isolated anti-HBc-positive livers are capable of transferring HBV infection to 50-78% of HBV-naïve 
recipients in the absence of preventative therapy [20,21]. In addition, HBV-naïve recipients who have not been vaccinated to prevent 
hepatitis B prior to OLT have an ongoing risk of acquiring parenterally transmitted HBV infections that require prompt diagnosis 
and treatment [22-24]. Mandatory hepatitis B vaccination for all HBV-naïve patients with diseases that could require OLT could 
significantly reduce this risk. 
2.  Impact of Strategies to Prevent and Treat HBV Infections in Transplant Recipients 
A report of OLT outcomes for HBV-infected patients in the U.S.A. from 1987 to 2002 underscores the positive, cumulative 
impact of advances to prevent and treat HBV reinfection [8]. This retrospective study analyzed cohorts of patients transplanted 
during three eras: Era 1 (1987-91, n= 6,708), Era 2 (1992-96, n= 13,995) and Era 3 (1997-2002, n= 20,730). Survival of patients was 
statistically significantly better for Era 2 compared with Era 1 (p<0.01) and Era 3 compared with Era 2 (p<0.01). No difference in 
survival was noted for Era 3 patients and patients transplanted for all non-HBV indications. Importantly, multivariate analysis 
showed that the effect of eras persisted even after consideration of confounding variables, such as donor and recipient age, ischemia 
time, severity of pre-OLT disease and presence of hepatocellular carcinoma. In contrast to earlier reports, Asian race [25-27] did not 
adversely affect survival and transplantation of patients with fulminant hepatitis B [9] did not enhance survival. The results of this 
study and those reported from Europe [13,28], indicate that application of innovative strategies to prevent and treat HBV infections 
before and after OLT are responsible for improved outcomes.  
3.  HBV Reinfection of Allografts 
Two mechanisms have been implicated in allograft reinfection: 1) rapid reinfection by HBV in the circulation of the recipient 
and/or 2) reinfection from HBV replicating in extrahepatic sites [29]. Since the former mechanism predominates in recipients with 
high HBV viral loads at the time of OLT, patients with active replication detected by insensitive molecular hybridization assays 
were considered as inferior candidates [9].  
Among patients receiving immunoprophylactic HBIG, late reinfections were attributed to either insufficient serum levels of 
anti-HBs to prevent infection from extrahepatic HBV [11,30] or emergence of anti-HBs escape mutations in the HBV S ORF 
[31,32]. Subsequent experience using LAM [33,34] and ADV [35] as prophylactic therapies has also demonstrated reinfections due 
to specific escape mutants. Thus, HBV-infected and HBV-naive recipients of livers from donors positive for isolated anti-HBc 
remain at risk for reinfection unless adequate preventative therapy is maintained.  
The impact of HBV genotype and precore mutants on reinfection has only recently been assessed. In London, genotypes A, D 
and A/D accounted for 89% of the European population undergoing OLT. Reinfection occurred in 40% a median of 10 months post-
OLT, and 22% died [36]. The rate of reinfection was not significantly greater for genotype D than A, and the reinfection rate in 
patients with genotype A/D was similar to genotype D patients. Among a heterogeneous population of recipients from the Middle 
East, Eastern and Western Europe, the U.S.A. and Asia, genotype D was present in 96% and A in 4% [37]. Reinfection occurred in 
22%, and no differences were noted among genotypes with respect to risk or prevalence of reinfection, development of LAM 
resistance or prevalence of precore mutations.  
4.  Management of Patients Prior to Transplantation 
Studies of HBIG monotherapy established active HBV replication before OLT as a dominant risk factor for reinfection [9,30]. 
Thus, therapies to reduce or eliminate HBV replication prior to OLT should result in a lower incidence of reinfection. The 
characteristics of ideal antiviral agent(s) would include low toxicity in the setting of decompensated cirrhosis and the rapid ability to 
eliminate HBV replication in patients with either acute or chronic infections. Despite clear progress in our ability to eliminate HBV 
replication, additional advances in drug development and application of antiviral strategies is required to achieve this goal. 
Alpha Interferon and Famciclovir 
The need for an extended period of interferon (IFN) therapy prior to OLT limited its potential for patients with fulminant or 
acute HBV infections, and its adverse effects, especially neutropenia and thrombocytopenia, resulted in poor tolerability in 
decompensated cirrhotics [38]. In a controlled trial of pre-OLT IFN therapy followed by HBIG immunoprophylaxis, the rate of 
reinfection was unchanged [39], while another study showed a reduced rate after IFN treatment [40]. In the same era, results of 
treatment with famciclovir were disappointing [41]. Neither IFN nor famciclovir are currently indicated treatments. Int. J. Med. Sci. 2005 2(1) 
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Lamivudine Monotherapy 
LAM has been extensively studied in OLT candidates (Table 1), is well tolerated in decompensated cirrhosis and results in 
undetectable HBV DNA using molecular hybridization in 63-100% of patients within 2-3 months [15, 42-52]. LAM is effective for 
both wild type (WT) and precore mutant (HBeAg-negative) strains [51]. Uninterrupted therapy is required prior to OLT, since 
premature cessation results in recurrent HBV replication [53]. Unfortunately, prolonged therapy, which is necessary for clinical 
benefit, increases the risk of developing LAM-resistant mutations as a result of amino acid substitutions in the YMDD motif 
encoded by the HBV RNA-dependent DNA polymerase gene [54]. The incidence of such mutations was 15-20% per year in the 
studies summarized in Table 1, and development of mutations can worsen liver failure [52]. Results of OLT in patients with YMDD 
mutations before transplantation have been reported for only a few patients and were conflicting [48,49,55,56]. Combination HBIG 
and LAM prevented recurrence in some [55,56], but not all recipients [48,49]. Since ADV and tenofovir have excellent efficacy 
against LAM-resistant HBV mutants [57,58], they should be used to treat patients with LAM resistance prior to OLT. 
Table 1. Results of Lamivudine Monotherapy Prior to OLT (*Mean or Median. NR; not reported.) 
 
The impact of lamivudine 
therapy for 3 to 6 months prior to 
OLT on hepatic function and 
transplant-free survival have been 
analyzed in several studies 
[46,47,50,52,59,60]. In one study, 
long-term treatment of 
decompensated cirrhotics on the OLT 
waiting list improved both hepatic 
function and survival compared to 
untreated, historical controls [47]. 
However, a retrospective analysis of 
LAM treatment of 309 patients listed 
for OLT showed no overall benefit in 
mortality before OLT or duration of 
transplant-free survival, except for 
patients with milder disease [50]. The Child-Turcotte-Pugh (CTP) score was the only variable significantly associated with pre-OLT 
death and prediction of OLT-free survival. In a prospective study of indefinite LAM pre-OLT therapy, 32 of 154 patients (21%) died 
and 25 of the 32 deaths occurred within 6 months of initiating therapy [52]. Bilirubin, creatinine and detectable serum HBV DNA 
were independent predictors of death within the 6 month period. In contrast, the estimated actuarial 3 yr survival for patients that 
survived ≥ 6 mo on therapy was 88%. Since rates of virological response to LAM were similar for patients who died or survived, 
both the initial and persistent severity of liver disease remain the best predictors of pre-OLT survival. Since liver allocation priority 
increases with liver disease severity in the U.S.A., LAM therapy does not jeopardize access to a donated organ.  
Adefovir Monotherapy 
ADV is active against WT HBV, precore mutants and LAM-resistant strains [61]. In a study of 128 patients with 
decompensated cirrhosis who had failed LAM therapy while awaiting OLT, ADV treatment for a median of 18 weeks reduced the 
HBV DNA level by 2.2 log10 by 4 week, by 4.1 log10 after 24 weeks and improved the CTP score [62]. Patients with renal 
dysfunction required ADV dose reductions. Although no patient developed ADV resistance in the study, ADV resistant mutants [63] 
have been recently described in the post-OLT setting [35]. Neither the clinical nor virological impacts of ADV mutations have been 
defined. As noted earlier, ADV is an excellent therapy for pre-OLT patients with LAM-resistant infections [19,62].  
Tenofovir Monotherapy 
Tenofovir disiproxil fumarate (TDF) is a nucleotide analogue that is FDA-approved for the treatment of HIV [64,65]. TDF also 
potently inhibits replication of WT and LAM-resistant HBV in infected patients but is not FDA-approved for this indication 
[58,66,67]. Since the antiviral effect of TDF is more rapid than that of ADV [68], it may be advantageous in patients with rapidly 
progressive disease or in those predicted to have a very short waiting period prior to OLT. Controlled trials of the safety and efficacy 
of TDF in pretransplant patients with WT and LAM-resistant infections should be performed.  
Entecavir Monotherapy 
Entecavir (ETV), a deoxyguanine nucleoside analogue, is a potent antiviral agent for both WT and LAM-resistant forms of 
HBV [69] that reduces HBV DNA levels to a greater degree than LAM [70]. ETV is currently in phase III clinical trials in non-
transplant patients, and ETV-resistant mutations have been reported in 2 patients to date [71]. Its future role in the treatment of 
pretransplant patients to eliminate HBV replication should be determined in future controlled trials. 
5.  Monotherapy to Prevent HBV Reinfection After Transplantation 
Hepatitis B Immune Globulin Monotherapy 
Long-term use of HBIG in the late 1980s in Europe and in the early 1990s in the U.S.A. significantly reduced the rate of 
reinfection and improved both graft and patient survival [9-12]. Although mechanism(s) of action of passive immunoprophylaxis 
with polyvalent anti-HBs antibodies remain unclear, the primary hypothesis is that anti-HBs bound to the surface of infectious HBV 
prevents HBV-receptor-mediated uptake by hepatocytes. Thus, HBIG is administered first during the anahepatic phase of OLT and 
subsequent dose regimens are designed to maintain an effective concentration of opsonizing anti-HBs. Immediately post-OLT, when 
the amount of circulating HBV remains high, a target trough level of anti-HBs of 500 IU/L has been recommended [72]. Later, when 
Authors N=  Duration  of 
Therapy* 
(months) 
Negative HBV 
DNA  
(%) 
Resistant 
Mutants  
(%) 
Reference 
Grellier, et al.  17  > 1  100  NR  42 
Markowitz, et al.  10  2.7  100  NR  43 
Villeneuve, et al.  35  19  100  25  44 
Lo, et al.  31  3.2  63  NR  45 
Perrillo, et al.  30  29  74  22  46 
Yao, et al.  23  13  100  10  47 
Seehofer, et al.  17  7.2  88  18  48 
Rosenau, et al.  19  12  NR  10.5  49 
Marzano, et al.  33  16  73  3  15 
Fontana, et al.  162  16  67  11  50 
Andreone, et al  25  4.5  92  8  51 
Fontana, et al  154  5.7  >80  27  52 Int. J. Med. Sci. 2005 2(1) 
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extrahepatic sites of replication become the source of HBV, a lower trough level of 100-150 IU/L has been considered protective if 
maintained indefinitely [7,72]. In the initial multicenter, European report, the rate of recurrent infection in patients receiving HBIG 
was directly correlated with the amount of HBV replication prior to and after OLT, being least in patients transplanted with 
fulminant hepatitis B (17%) and greatest in cirrhotics (67%) [9]. The rate of reinfection in patients receiving HBIG who were 
transplanted with fulminant hepatitis delta virus (HDV) infection and HDV cirrhosis was 40% and 32%, respectively [9]. In patients 
with active HBV replication pre-OLT, reinfection could be prevented by using higher doses of HBIG to maintain anti-HBs levels > 
500 IU/L [10,11]. Overall, HBIG immunoprophylaxis reduced reinfection rates for cirrhotic patients to 16-35% in the presence of 
replicating HBV pre-OLT and to 0-15% in the absence of replication [9,11,12,28]. In Europe, an intravenous formulation of HBIG 
made infusion the preferred route [9]. Intramuscular formulations available in the U.S.A. [73] were most often infused, but 
intramuscular injections were also effective [74,75]. The need to monitor trough anti-HBs levels can be overcome by using a fixed 
dose of 10,000 IU once monthly [10]. However, monitoring of serum anti-HBs trough levels to define variability in immunoglobulin 
catabolism permits individualized dosing and significant cost savings.  
HBIG therapy is safe and most adverse events have primarily been ascribed to the intravenous administration of intramuscular 
preparations [10,72]. A report of mercury toxicity in one patient has not been verified by others [76]. Unfortunately, the indefinite 
administration of HBIG remains expensive, and repeated measurements of trough anti-HBs levels add to the costs.  
Despite HBIG immunoprophylaxis, late reinfection occurs, especially in patients with active pre-OLT replication of HBV. Late 
reinfections can be caused by failing to maintain adequate anti-HBs levels or by emergence of escape mutations, resulting selective 
pressure of anti-HBs. The primary escape mutation is G145R in the small surface protein “a” determinant that conformationally 
prevents anti-HBs binding [31,32,77]. Once HBIG is discontinued, WT HBV reemerges [31].  
Lamivudine Monotherapy 
The goal of LAM monotherapy after OLT is to prevent reinfection of the allograft by inhibiting HBV replication in 
extrahepatic sites. Unfortunately, post-OLT monotherapy has been associated with reinfection with LAM-resistant YMDD mutants 
in 23-50% of patients, with increased mortality in some [42,45,46,78,79]. Thus, LAM monotherapy for post-OLT prophylaxis has 
been abandoned in favor of combination therapies. 
6.  Combination Therapies to Prevent HBV Reinfection After Transplantation 
Hepatitis B Immune Globulin and Lamivudine 
The combination of LAM therapy pre- and post-OLT with HBIG post-OLT has become the standard of care for most liver 
transplant programs (Table 2). Multiple studies showed that the mean reinfection rate was only 5.2% (range 0-18%) after 1 to 2 
years, [14,15,18,28,43,48,49,75,80,81]. Importantly, using highly sensitive PCR, circulating HBV DNA was undetectable in most 
patients after OLT [7,28,82]. The mechanism(s) contributing to the efficacy of combination LAM and HBIG remain poorly defined. 
Postulated mechanisms include the synergy of: 1) LAM reducing HBV replication and altering synthesis of HBsAg necessary for 
generation of HBIG escape mutations and 2) HBIG preventing the receptor-mediated entry of HBV into hepatocytes and 
extrahepatic cells required for production of escape mutations in the YMDD motif. In addition to efficacy, combination therapy is 
more cost effective because the dosage of expensive HBIG can be reduced [14,49]. Combination therapy also permitted effective 
conversion of a high dose intravenous HBIG regimen to a lower dose intramuscular regimen in 98% of patients [74]. A recent study 
demonstrated efficacy and further cost reductions as a result of injecting HBIG only when anti-HBs levels fell below 70 IU/L [83]. 
Given differences in HBIG preparations and variations in their use, it is important to note that the optimal protocol for safety, 
efficacy and cost of combination LAM and HBIG prophylaxis has not been defined. 
Table 2. Effect of Combination Therapy with HBIG and Lamivudine to Prevent HBV Reinfection After OLT. (IV, intravenous; IM, 
intramuscular, NR, not reported.) 
Authors N=  Pre-OLT 
Duration* of 
LAM 
(mos) 
HBV DNA 
Negative at 
OLT 
(%) 
HBIG 
Route of 
Administration 
HBV 
Reinfection 
(%) 
Reference 
Markowitz, et al.  14  3  93  IV  0  43 
Yao, et al.  10  8.6  80  IV then IM  10  75 
Yoshida, et al.  7  NR  100  IM  0  80 
Angus, et al.  37  3.2  NR  IM  3  18 
Marzano, et al.  33  4.6  100  IV  4  15 
McCaughan, et al.  9  0  NR  IM  0  81 
Rosenau, et al.  21  4.6  77  IV  10  49 
Roche, et al.  15  4.6  73  IV  7  28 
Han, et al.  59  NR  NR  IV  0  14 
Seehofer, et al.  17  10.6  71  IV  18  48 
 
Development of LAM-resistant mutants during LAM monotherapy pre-OLT (Table 1) complicates analysis of the benefits of 
combination LAM and HBIG therapy post-OLT, since most patients with LAM resistance pre-OLT have received LAM and HBIG 
combination therapy after OLT (Tables 1 and 2). One such patient had not developed reinfection 32 months after OLT [56], while 
two patients rapidly developed reinfection 13 and 75 days post operatively [84]. ADV treatment of 128 pre-OLT patients with LAM 
resistance showed undetectable HBV DNA (<400 copies/ml) in 81% of those treated for 48 weeks, and 50-83% showed concurrent 
improvement in liver tests [62]. These reports indicate that ADV should be used once LAM resistance is detected pre-OLT and that 
combination ADV and HBIG be used after transplantation.  Int. J. Med. Sci. 2005 2(1) 
 
45
Hepatitis B Immune Globulin and Ganciclovir 
Intravenous ganciclovir failed to provide additional prophylaxis against HBV reinfection in patients receiving HBIG [85] and 
should no longer be used.  
Hepatitis B Immune Globulin and Adefovir 
Controlled trials of this combination therapy have not been reported, but the lower incidence of escape mutations to ADV [35] 
compared to LAM enhances the rationale for such studies.  
7.  Sequential and Modified Combination Therapies 
To assess the reinfection rate among low risk patients receiving HBIG, patients were randomized to continue HBIG or to 
discontinue it and begin LAM [86]. Low risk was defined as an absence of detectable HBV DNA at the time of OLT and absence of 
reinfection for a minimum of 6 months post-OLT. After one year, reinfection occurred in 20% of patients in each group, but the 
finding of circulating HBV DNA by PCR in 2 of 11 receiving HBIG and 5 of 10 receiving LAM suggests that reinfection would be 
likely in additional patients with longer observation. Discontinuation of HBIG from a combination regimen of HBIG and LAM was 
also studied in 14 randomly selected patients from a group of 29 who were HBV DNA negative at the time of OLT (17 induced by 
LAM pre-OLT) and had received combination therapy for one month [87]. Although none of the patients developed clinical 
reinfection during 18 months of observation, HBV DNA and polymerase mutations were detected in both groups. In a non-
randomized study, no reinfections were identified after 12 months in 16 patients who were treated with LAM monotherapy after 
having received HBIG for 24 months [88]. Despite the advantages of ease of patient care and cost reduction, discontinuation of 
HBIG remains risky because there are no definitive tests to identfy patients have cleared HBV from liver and plasma, and once 
reinfection occurs, HBIG cannot be reinstituted. Indeed, HBV DNA has been detected in the liver, serum or leukocytes in 50% of 
HBsAg-negative patients treated for 10 years with HBIG prophylaxis [28] and among patients treated with combination HBIG and 
LAM [15,86].  
8.  Manipulation of the Immune Response 
Adoptive Transfer of HBV Immunity from Donor Livers: Effective adoptive transfer of humoral immunity to hepatitis B 
was first demonstrated in recipients of bone marrow transplants from immune donors [89,90]. Transplantation of livers from HBV 
vaccinated woodchucks into HBV-infected recipients also has been shown to reduce or delay severity of reinfection, presumably due 
to the effects of HBV-specific memory cells among passenger leukocytes [91]. An initially low recurrence rate in a Chinese cohort 
receiving LAM monotherapy was hypothesized to be due to transplantation of passenger leukocytes in HBV-immune donors that 
produced anti-HBs in the recipients [45]. A recent report ascribed the successful elimination of a de novo HBV infection post-OLT 
with development of anti-HBs to the fact that the liver donor had been immunized against hepatitis B [92].  
Vaccination After Transplantation: The prospect of generating active immunity against HBsAg epitopes remains an 
intriguing strategy that could obviate the need for passive immunoprophylaxis. Following replacement of HBIG with HBV 
vaccination, 14 of 17 responders (anti-HBs levels of 10-100 IU/L) did not develop reinfection after a median observation period of 
14 months (range 3-50 months) [93]. In contrast, discontinuation of HBIG with triple course of vaccine produced detectable anti-
HBs levels in only 18% of recipients in another study [94]. HBV vaccination of pediatric patients post-OLT resulted in detectable 
anti-HBs in 17 or 19 (89%) [95]. Among 9 patients who received livers from anti-HBc-positivie donors, anti-HBs developed in 7 
and only 1 of the non-responders developed de novo HBV infection. New strategies to enhance immunogenicity of hepatitis B 
vaccines in immunosuppressed patients post-OLT also have been reported. Repeated immunization of patients receiving HBIG who 
were HBV DNA negative prior to OLT with multiple doses of recombinant HBV vaccine emulsified in novel adjuvants resulted in 
substantial anti-HBs levels (range 721-83,121 IU/L) in 80% and permitted discontinuation of HBIG [96]. Although preliminary, 
these results provide proof of principle that HBV vaccination can generate protective levels of anti-HBs in immunosuppressed 
patients.  
Immunosuppressive Regimen: The majority of studies of the prevention of HBV reinfection have been from centers using a 
combination of steroids and either cyclosporine or tacrolimus as immunosuppression. Early steroid withdrawal has been considered 
desirable because it limits the duration of stimulation of the glucocorticoid response element in the HBV genome [97]. Although 
rapid withdrawal of steroids can be achieved [98], its impact on the incidence and timing of HBV reinfection has not been 
systematically studied. The increasing use of nucleoside and nucleotide therapies to eliminate HBV replication prior to OLT and the 
effectiveness of post-OLT preventative strategies despite immunosuppression argue against an urgent need for such studies.  
9.  Prevention of Transmission from Isolated Anti-HBc Positive Donor Livers 
Because of the shortage of deceased donor organs, livers from isolated anti-HBc-positive donors (negative for HBsAg and anti-
HBs) are being routinely transplanted into HBV-naïve recipients [99]. In the absence of preventative measures, HBV infection 
occurred in 50% to 78% of such recipients in Spain [20] and the U.S.A. [21] , respectively. However, livers from anti-HBc-positive 
donors can be successfully used without reinfection if recipients receive prophylactic therapy with a combination of HBIG and LAM 
[100,101] or LAM monotherapy [102]. Recent reports also indicate that anti-HBc positivity in the donor is not a contraindication for 
live donor liver transplantation when effective prophylaxis is given [103,104]. 
10. Therapy for Established Reinfection After Transplantation 
Lamivudine and Adefovir: As discussed above, the majority of hepatitis B OLT recipients are currently treated with LAM 
preoperatively (Table 1) and a combination of HBIG and LAM postoperatively (Table 2). Prolonged therapy with LAM pre-OLT 
results in a progressive risk of developing resistant YMDD mutants post-OLT [42,45,46,78,79]. The effectiveness of ADV treatment 
of LAM-resistant mutations has been reported in patients with significant reinfections with YMDD mutants post-OLT [62,105]. 
Thus, ADV treatment should be started as soon as YMDD mutations are identified pre- or post-OLT. Since ADV resistance also has 
been identified in an OLT recipient [35], serum HBV DNA should be serially monitored in patients treated long-term with ADV.  Int. J. Med. Sci. 2005 2(1) 
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Tenofovir:  TDF is a potent inhibitor of both WT and LAM-resistant HBV replication but is not FDA-approved for this 
indication [58,66-68]. The acelerated onset of antiviral activity of TDF against HBV compared to ADV [66] suggests that it should 
be considered for patients with rapidly progressive reinfections. Controlled trials of safety and efficacy in patients with reinfections 
should be performed.  
Entecavir: ETV is also a potent inhibitor of both WT and LAM-resistant forms of HBV [106,107]. ETV was superior to LAM 
in reducing HBV DNA in patients with chronic hepatitis B, suggesting a potential role in the treatment of severe reinfections [70]. 
However, the role of ETV in the treatment of HBV post-OLT has not been determined in controlled trials. 
Alpha Interferon: Although IFN therapy is difficult to tolerate and manage post-OLT, it has been successfully used to treat 
HBV reinfections [108-110]. Using standard TIW dosing for a median of 23.5 weeks, 4 of 14 (29%) reinfected patients had a 
sustained virological response with undetectable HBV DNA and 2 (14%) had seroconversion of HBeAg [110]. IFN treatment of 
LAM-resistant reinfections in 4 patients resulted in reduction of HBV DNA levels in all, loss of detectable HBV DNA in 3 and 
sustained virological responses in 2 [108]. Overall these favorable results do not outweigh the liabilities of IFN treatment of 
reinfections compared to the safety and tolerability of nucleoside and nucleotide agents. 
Ganciclovir:  Intravenous ganciclovir persistently inhibited HBV replication in reinfected patients post-OLT [111], but its 
overall efficacy was poor [85,111,112]. It is now only of historical interest. 
11. Treatment of De Novo HBV Infections 
Unvaccinated, HBV-naïve patients are at risk of acquiring hepatitis B post-OLT. In addition, transplantation of livers harboring 
occult HBV and those from donors with isolated anti-HBc-positivity represent additional risks of infection in naïve transplant 
recipients. Although famciclovir therapy has been reported to be beneficial [113], de novo HBV infections after OLT [24,114] 
should be treated with FDA-approved agents specific for HBV. Both LAM [115] and ADV [92] have been effective.  
12. Future Directions 
Development of new antiviral agents to treat HBV infection promises to provide a greater choice of effective medications and 
new opportunities to study combination therapies to eliminate HBV replication prior to after OLT. The goals of such combination 
therapies would include not only safety and antiviral efficacy, but elimination of the risk of viable escape mutations. Since patients 
without HBV replication prior to OLT have the lowest risk of reinfection, the dominant strategy will be the use of antiviral agents 
alone or in combination to terminate HBV replication. The effectiveness of LAM monotherapy pre- and post-OLT represents proof 
of principle that combination antiviral therapies post-OLT should be capable of preventing reinfection from extrahepatic reservoirs 
of HBV if escape mutants do not emerge. If effective oral therapies are developed, passive immunoprophylaxis with HBIG will 
likely be reserved for patients with residual circulating HBV DNA at the time of OLT.  Increased sophistication in detecting occult 
HBV in liver biopsies, circulating leukocytes and extrahepatic sites may ultimately be exploited to identify patients who no longer 
require post-OLT therapy. Further development of HBV vaccines, especially those containing the product of the PreS1 ORF, and 
more potent adjuvants may permit effective therapeutic immunization of post-OLT patients, despite immunosuppression. However, 
the greatest achievement would be the resolve to provide worldwide immunization with HBV vaccine early in life to eradicate HBV 
infection and the need for transplantation for this indication.  
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